Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Organoid Models of Tumor Immunology
Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 402
Arginine-dependent immune responses
Martí i Líndez, A.-A., & Reith, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03828-4 · Cited by 354
“The MDSC population encompasses diverse types of developmentally immature cells at different stages of myelopoiesis [166].”
BackgroundThe impact of psychosocial stress and stress management on immune responses in patients with cancer
Antoni, M. H., & Dhabhar, F. S. (2019) · Cancer · doi:10.1002/cncr.31943 · Cited by 394
Fousek, K., Horn, L. A., & Palena, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107692 · Cited by 359
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
“1), which are used for identification of MDSCs subsets and to distinguish MDSCs from neutrophils and monocytes (2, 12).”
MethodMohammadpour, H., MacDonald, C. R., Qiao, G., Chen, M., Dong, B., Hylander, B. L., McCarthy, P. L., Abrams, S. I., & Repasky, E. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129502 · Cited by 320
Contribution of Angiogenesis to Inflammation and Cancer
Aguilar-Cazares, D., Chavez-Dominguez, R., Carlos-Reyes, A., Lopez-Camarillo, C., Hernadez de la Cruz, O. N., & Lopez-Gonzalez, J. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01399 · Cited by 317
“This set of immune cells and the molecules they secrete then activate the PI3K and NF-κB signaling pathways for promoting the EMT and vasculogenic mimicry (81, 82).”
BackgroundTumor microenvironment in gastric cancers
Oya, Y., Hayakawa, Y., & Koike, K. (2020) · Cancer Science · doi:10.1111/cas.14521 · Cited by 328
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 291
“Several recent studies have shown that MDSCs also produce exosomes, whose contents are implicated in their own chemotaxis, survival, pro-metastatic, and immunosuppressive activity (165).”
BackgroundHaist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“Most notably, recent reports suggest that MDSC-mediated immunosuppression substantially contributes to tumor immune evasion [28,251].”
BackgroundChen, H., Pan, Y., Zhou, Q., Liang, C., Wong, C.-C., Zhou, Y., Huang, D., Liu, W., Zhai, J., Gou, H., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.024 · Cited by 277
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 258
How chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
“Similar to severe infections that trigger emergency haematopoiesis, solid cancers remotely induce an accelerated release of immature myeloid cells with features of granulocytes or monocytes, collectively referred to as MDSCs, from the bone marrow 185 .”
The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
Wang, H., Yung, M. M. H., Ngan, H. Y. S., Chan, K. K. L., & Chan, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126560 · Cited by 254
“These tumor-educated myeloid cells, particularly tumor-associated macrophages (TAMs), are able to retard anti-tumor immune responses through the synthesis of immunosuppressive cytokines, the expression of T cell coinhibitory molecules, and the consumption of amino acids that are critical for the activity of effector T…”
BackgroundRegulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
Baumann, T., Dunkel, A., Schmid, C., Schmitt, S., Hiltensperger, M., Lohr, K., Laketa, V., Donakonda, S., Ahting, U., Lorenz-Depiereux, B., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0666-9 · Cited by 225
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function
Shaul, M. E., & Fridlender, Z. G. (2018) · The FEBS Journal · doi:10.1111/febs.14524 · Cited by 216
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
“The simple dichotomy of M1/M2 macrophages cannot account for the complexity of TAM heterogeneity (Ostuni et al., 2015).”
BackgroundWang, Y., Yin, K., Tian, J., Xia, X., Ma, J., Tang, X., Xu, H., & Wang, S. (2019) · Advanced Science · doi:10.1002/advs.201901278 · Cited by 211
Mechanisms of immune escape in the cancer immune cycle
Tang, S., Ning, Q., Yang, L., Mo, Z., & Tang, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106700 · Cited by 178
Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-Related Diseases
Bleve, A., Motta, F., Durante, B., Pandolfo, C., Selmi, C., & Sica, A. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08909-7 · Cited by 153
Unterman, A., Sumida, T. S., Nouri, N., Yan, X., Zhao, A. Y., Gasque, V., Schupp, J. C., Asashima, H., Liu, Y., Cosme, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27716-4 · Cited by 179
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 168
Mohammadpour, H., MacDonald, C. R., McCarthy, P. L., Abrams, S. I., & Repasky, E. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109883 · Cited by 180
“These data suggest that signaling through the β2-AR on MDSCs is a key driver of the intracellular events that lead to immune suppression and elevated tumor growth rates. β2-AR signaling in MDSCs increases autophagy Autophagy also plays a critical role in the immunosuppressive function of MDSCs in the TME by promoting…”
BackgroundInfluentialSiret, C., Collignon, A., Silvy, F., Robert, S., Cheyrol, T., André, P., Rigot, V., Iovanna, J., van de Pavert, S., Lombardo, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03070 · Cited by 156
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03048-x · Cited by 154
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
Liu, L., Bai, H., Wang, C., Seery, S., Wang, Z., Duan, J., Li, S., Xue, P., Wang, G., Sun, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.016 · Cited by 149
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
Chanier, T., & Chames, P. (2019) · Antibodies · doi:10.3390/antib8010013 · Cited by 150
“M2 macrophages, myeloid derived suppressor cells (MDSCs) and tolerogenic dendritic cells promote an immunosuppressive environment and favor tumor growth and angiogenesis [71].”
BackgroundDamage-associated molecular patterns (DAMPs) in diseases: implications for therapy
Lin, H., Xiong, W. G., Fu, L., Yi, J., & Yang, J. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00305-3 · Cited by 151
Zhang, F., Stephan, S. B., Ene, C., Smith, T. T., Holland, E. C., & Stephan, M. T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0306 · Cited by 142
Holtzhausen, A., Harris, W. P., Ubil, E., Hunter, D. M., Zhao, J., Zhang, Y., Zhang, D., Liu, Q., Wang, X., Graham, D. K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0008 · Cited by 145
“MDSCs are a heterogeneous population of bone marrow-derived, immature myeloid cells (17,32-34).”
BackgroundRecent updates on cancer immunotherapy
Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 145
“Complementary to Treg modulation, MDSC, macrophage, and type II NK cells in TME may be targeted to lift their suppression of anti-tumor immunity.(3,50) In this context, antagonistic anti-IL-18 reduces MDSC, leading to attenuation of multiple myeloma progression,(51) and antibodies against MICA on tumor cells increase…”
BackgroundWang, W., Su, B., Pang, L., Qiao, L., Feng, Y., Ouyang, Y., Guo, X., Shi, H., Wei, F., Su, X., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0447-2 · Cited by 136
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Weber, R., Riester, Z., Hüser, L., Sticht, C., Siebenmorgen, A., Groth, C., Hu, X., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000949 · Cited by 139
Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity
Pawelec, G., Verschoor, C. P., & Ostrand‐Rosenberg, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01099 · Cited by 140
“Because the role of MDSCs in cancer has been subject to considerable recent scrutiny [reviewed in (11, 12)], we will only very briefly cover this issue and focus more on the importance of MDSCs in other conditions.”
BackgroundSelf-citationzhao, J., Zhang, Z., Xue, Y., Wang, G., Cheng, Y. G., Pan, Y., Zhao, S., & Hou, Y. (2018) · Theranostics · doi:10.7150/thno.29746 · Cited by 127
“Myeloid-derived suppressor cells (MDSCs) are thought to impair antitumor immunity [59, 60].”
BackgroundVetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125
“The above mechanism results in the inability of T cells to become activated [24,44], while the oxidative stress leads the target cell to apoptosis [36].”
BackgroundInfluentialMiska, J. M., Rashidi, A., Lee-Chang, C., Gao, P., Lopez‐Rosas, A., Zhang, P., Burga, R. A., Castro, B. A., Xiao, T., Han, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc8929 · Cited by 127
The Generation and Identity of Human Myeloid-Derived Suppressor Cells
Bergenfelz, C., & Leandersson, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00109 · Cited by 125
“The functional aspects of G-MDSCs, have been excellently reviewed elsewhere and will therefore not be covered in detail here (30, 39).”
BackgroundB lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses
Rossetti, R. A. M., Lorenzi, N. P. C., Yokochi, K., Rosa, M. B. S. D. F., Benevides, L., Margarido, P. F. R., Baracat, E. C., Carvalho, J. P., Villa, L. L., & Lepique, A. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199034 · Cited by 117
Zhang, Z., Yu, Q.-Q., Zhang, X.-N., Wang, X., Su, Y., He, W., Li, J., Wan, Y., & Jing, X. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119259 · Cited by 121
Gunda, V., Gigliotti, B., Ashry, T., Ndishabandi, D., McCarthy, M., Zhou, Z., Amin, S., Lee, K. E., Stork, T., Wirth, L., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32041 · Cited by 111
“Therefore, the increase in MDSCs with lenvatinib is paradoxical; receptors targeted by lenvatinib such as VEGFR, c-kit, PDGFR, FGFR, and further downstream, STAT3 and STAT-5, have all been implicated in MDSC accumulation and/or MDSC immunosuppressive function.(43) The mechanism of lenvatinib’s expansion of MDSCs remai…”
BackgroundEpithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Tomić, S., Joksimović, B., Bekić, M., Vasiljević, M., Milanović, M., Čolić, M. J., & Vučević, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00475 · Cited by 111
Zhou, Z., Van der Jeught, K., Fang, Y., Yu, T., Li, Y., Ao, Z., Liu, S., Zhang, L., Yang, Y., Eyvani, H., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00805-x · Cited by 107
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Curti, B. D., Koguchi, Y., Leidner, R. S., Rolig, A. S., Sturgill, E. R., Sun, Z., Wu, Y., Rajamanickam, V., Bernard, B. M., Hilgart-Martiszus, I., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002371 · Cited by 108
“In contrast, 100% of patients achieving an objective response (CR or PR) could be characterized by both the percent of circulating PD-1+ effector memory CD8+ T cells and the extent of Gal-3+ tumor cells present at baseline (figure 4E).”
Tan, D. S. W., Felip, E., de Castro, G., Solomon, B., Greystoke, A., Cho, B. C., Cobo, M., Kim, T. M., Ganguly, S., Carcereny, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00980 · Cited by 108
ER stress activates immunosuppressive network: implications for aging and Alzheimer’s disease
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01904-z · Cited by 96
“, those secreted by the ER-stressed nonimmune cells, are the major inducers of immunosuppressive phenotypes in infiltrated myeloid cells [111, 112, 133].”
BackgroundCAR-T cells: Early successes in blood cancer and challenges in solid tumors
Dana, H., Chalbatani, G. M., Jalali, S. A., Mirzaei, H. R., Grupp, S. A., Suarez, E. R., Rapôso, C., & Webster, T. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.020 · Cited by 108
Current Approaches for Glioma Gene Therapy and Virotherapy
Banerjee, K., Núñez, F. J., Haase, S., McClellan, B. L., Faisal, S. M., Carney, S. V., Yü, J., Alghamri, M. S., Asad, A. S., Candia, A. J. N., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.621831 · Cited by 109
“MDSCs play a major immune suppressive role in the TME and are correlated with glioma progression and therapeutic resistance (Kamran et al., 2018b; Ostrand-Rosenberg and Fenselau, 2018).”
BackgroundZalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 107
“MDSCs can also secrete VEGF (Figure 2), creating, together with the tumor cells, a positive autocrine feedback loop in the TME (373, 374).”
BackgroundImmunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 104
“These reprogrammed myeloid cells are present in the peripheral blood and tumors of cancer patients and can diminish the anti-tumor effects of immunotherapeutics [3].”
BackgroundA Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00262 · Cited by 101
“MDSCs localize to the tumor microenvironment through chemokines such as VEGF (50).”
BackgroundEarly stratification of radiotherapy response by activatable inflammation magnetic resonance imaging
Zhou, Z., Deng, H., Yang, W., Wang, Z., Lin, L., Munasinghe, J., Jacobson, O., Liu, Y., Tang, L., Ni, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16771-y · Cited by 98
Ibrahim, A., Abdalsalam, N. M. F., Liang, Z., Tariq, H. K., Li, R., Afolabi, L. O., Rabiu, L., Chen, X., Xu, S., Xu, Z., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00886-9 · Cited by 101
“Following treatment with monoclonal antibodies (mAbs) targeting PD-1 or PD-L1, 17 – 28% of patients with advanced cancers exhibit partial or complete remissions [24].”
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 100
“MDSCs can be abundant in PDAC due to its richness in MDSC chemoattractant molecules such as vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), tumor necrosis factor-alpha, and GM-CSF [111, 113].”
BackgroundInfluentialBefriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
Lindo, L., Wilkinson, L., & Hay, K. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618387 · Cited by 99
IL-33–mediated IL-13 secretion by ST2+ Tregs controls inflammation after lung injury
Liu, Q., Dwyer, G. K., Zhao, Y., Li, H., Mathews, L. R., Chakka, A. B., Chandran, U. R., Demetris, J. A., Alcorn, J. F., Robinson, K. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123919 · Cited by 122
Albonici, L., Giganti, M. G., Modesti, A., Manzari, V., & Bei, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122970 · Cited by 93
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
Roselli, E., Faramand, R. G., & Davila, M. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142030 · Cited by 100
“The presence of immunosuppressive cells in the TME, such as Tregs, MDSCs, and M2-like macrophages, has been shown to inhibit the antitumor ability of tumor-infiltrating T cells (111, 112).”
BackgroundLi, J., Shu, X., Xu, J., Su, S. M., Chan, U. I., Mo, L., Liu, J., Zhang, X., Adhav, R., Chen, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29151-5 · Cited by 101
Leone, K., Poggiana, C., & Zamarchi, R. (2018) · Diagnostics · doi:10.3390/diagnostics8030059 · Cited by 103
“MDSCs are heterogeneous, immature myeloid cells comprising a polymorphonuclear subset (PMN-MDSCs) and a monocytic subset (M-MDSCs), which can be respectively distinguished from granulocytes and monocytes due to their high immunosuppressive activity [75].”
BackgroundPro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site
Nasrollahzadeh, E., Razi, S., Keshavarz‐Fathi, M., Mazzone, M., & Rezaei, N. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02616-6 · Cited by 89
Sarkar, O. S., Donninger, H., Rayyan, N. A., Chew, L. C., Stamp, B. F., Zhang, X., Whitt, A. G., Li, C., Hall, M. B., Mitchell, R. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3736 · Cited by 86
Myeloid-derived suppressor cells (MDSC): an important partner in cellular/tissue senescence
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2018) · Biogerontology · doi:10.1007/s10522-018-9762-8 · Cited by 84
The Immune Microenvironment in Prostate Cancer: A Comprehensive Review
Novysedlák, R., Guney, M., Khouri, M. A., Bartolini, R., Foley, L. K., Benešová, I., Ozaniak, A., Novák, V., Veselý, Š., Pacas, P., et al. (2024) · Oncology · doi:10.1159/000541881 · Cited by 91
“The involvement of these MDSCs in the TIME largely attenuates the anti-tumor ef fi cacy of cytotoxic T cells [70].”
Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2
Cherfils‐Vicini, J., Iltis, C., Cervera, L., Pisano, S., Croce, O., Sadouni, N., Győrffy, B., Collet, R., Renault, V. M., Rey‐Millet, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100012 · Cited by 87
“In the same Matrigel plug assay, we observed that the expression of three immunosuppressive molecules, arginase 1 (Arg-1), IL-10, and TGF-b (Ostrand-Rosenberg & Fenselau, 2018), which are expressed by MDSCs to trigger NK and T cell suppression (Gabrilovich & Nagaraj, 2009; Nagaraj & Gabrilovich,…”
InfluentialTang, C., Sun, H., Kadoki, M., Han, W., Ye, X., Makusheva, Y., Deng, J., Feng, B., Qiu, D., Tan, Y. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37229-x · Cited by 86
Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses
Foglia, B., Beltrà, M., Sutti, S., & Cannito, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087463 · Cited by 89
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 87
Vatter, F. A. P., Cioffi, M., Hanna, S. J., Castarède, I., Caielli, S., Pascual, V., Matei, I. R., & Lyden, D. C. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202579 · Cited by 84
Immunotherapy in breast cancer
Bayraktar, S., Batoo, S. A., Okuno, S. H., & Glück, S. (2019) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_2_19 · Cited by 84
“Accumulating evidence in recent years have even highlighted them as a major driver of an immunosuppressive tumor microenvironment.[35] The research shows that although ICI may prove to be effective, therapeutic resistance occurs in the majority of patients, leading to tumor progression.”
Critical immunosuppressive effect of MDSC‑derived exosomes in the tumor microenvironment
Rashid, M. H., Borin, T. F., Ara, R., Piranlioglu, R., Achyut, B. R., Körkaya, H., Liu, Y., & Arbab, A. S. (2021) · Oncology Reports · doi:10.3892/or.2021.7936 · Cited by 82
“tumor‐promoting phenotype (M2‐macrophage) (14) and by inhibiting natural killer (NK) cell‐mediated cytotoxicity (15).”
MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target
Ma, C., Zhang, Q., & Greten, T. F. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104295 · Cited by 81
“As a component of the tumor microenvironment, MDSCs suppress anti-tumor immunity and promote tumor progression[12, 14].”
BackgroundMDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 84
“Following isolation, MDSCs need to be immediately tested in experiments because PMN-MDSCs are cryosensitive and have short ex vivo life-spans [47,48].”
BackgroundCancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
Lewinsky, H., Gunes, E. G., David, K., Radomir, L., Kramer, M. P., Pellegrino, B., Shahor, M. P., Chen, J., He, T.-F., Mansour, A. G., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141683 · Cited by 78
“In addition, S100A8 and S100A9 also act as chemoattractants for the MDSCs (39).”
BackgroundKing, R. J., Shukla, S. K., He, C., Vernucci, E., Thakur, R., Attri, K. S., Dasgupta, A., Chaika, N. V., Mulder, S. E., Abrego, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02132-6 · Cited by 75
“Similar to PDAC, other cancer models highlight the importance of GM-CSF in an early influx of MDSCs in premalignant lesions [26].”
ResultOstrand‐Rosenberg, S., Beury, D. W., Parker, K. H., & Horn, L. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02388-8 · Cited by 72
Self-citationParra, E. R., Ferrufino-Schmidt, M. C., Tamegnon, A., Zhang, J., Solis, L., Jiang, M., Ibarguen, H., Haymaker, C., Lee, J. J., Bernatchez, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88156-0 · Cited by 65
Hypoxia as a Modulator of Inflammation and Immune Response in Cancer
Castillo‐Rodríguez, R. A., Trejo‐Solís, C., Cabrera‐Cano, A., Gómez‐Manzo, S., & Dávila‐Borja, V. M. (2022) · Cancers · doi:10.3390/cancers14092291 · Cited by 81
Ruiz, D. F. Z., Kim, D. V., Norwood, K., Saldana-Morales, F. B., Kim, M., Ng, C., Callaghan, R., Uddin, M., Chang, L.-C., Longman, R., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2119054 · Cited by 74
“MDSCs are similar to neutrophils and both inhibit T cell recruitment and suppress T cell responses within the tumor.(38,39) We also found changes in recruitment of lymphoid cells to tumors in 541–15 colonized mice.”
BackgroundSidiropoulos, D. N., Rafie, C. I., Jang, J. K., Castanon, S., Baugh, A. G., Gonzalez, E., Christmas, B. J., Narumi, V. H., Davis-Marcisak, E. F., Sharma, G., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0170 · Cited by 73
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD
Koehn, B. H., Saha, A., McDonald-Hyman, C. S., Loschi, M. L., Thangavelu, G., Ma, L., Zaiken, M. C., Dysthe, J., Krepps, W., Panthera, J., et al. (2019) · Blood · doi:10.1182/blood.2019001950 · Cited by 70
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
Belderbos, R. A., Aerts, J. G. J. V., & Vroman, H. H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.007 · Cited by 73
“Furthermore, HIF-1a induces differentiation of mMDSCs into tumor-associated macrophages (TAMs) through the downregulation of phosphorylated signal transducer and activator of transcription 3 (pSTAT3), indicating that the TME can influence both immune cell function and differentiation.(40,41)”
BackgroundCell interactions in the bone marrow microenvironment affecting myeloid malignancies
Kokkaliaris, K. D., & Scadden, D. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002127 · Cited by 74
“In particular, myeloid-derived suppressor cells (MDSCs) appear to be induced.(43) These are a population of CD33(1)CD11b(1)HLA DR cells with the potential to induce T-cell tolerance,(44) recruit T regulatory cells (Tregs) and impair natural killer (NK) function through metabolic and cytokine perturbations of the micro…”
BackgroundAngiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice
Yang, S., Fang, Y., Ma, Y., Wang, F., Wang, Y., Jia, J., Yang, Y., Sun, W., Zhou, Q., & Li, Z. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70313 · Cited by 71
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 70
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 72
Guan, L., Nambiar, D. K., Cao, H., Viswanathan, V., Kwok, S., Hui, A. B., Hou, Y., Hildebrand, R., von Eyben, R., Holmes, B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1903 · Cited by 69
Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer
Chaib, M., Chauhan, S. C., & Makowski, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00351 · Cited by 67
Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?
Rossi, E. M. C., & Zamarchi, R. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00958 · Cited by 67
Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology
Ostrand‐Rosenberg, S., Lamb, T. J., & Pawelec, G. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200914 · Cited by 63
Self-citation
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.